Showing results (1-10 of 37) with videos related to
Sort By:
Pageof 4
Current Atherosclerosis Reports|February 16, 2016
Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin RegimensRichard L Dunbar, Harsh GoelCurrent Atherosclerosis Reports|March 3, 2016
Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin MimeticsHarsh Goel, Richard L DunbarPreventive Cardiology|April 30, 2005
The unsung perils of peripheral arterial disease: a malady in search of a patientRichard L Dunbar, Emile R MohlerCleveland Clinic Journal of Medicine|August 27, 2005
Demystifying triglycerides: a practical approach for the clinicianRichard L Dunbar, Daniel J RaderThe Journal of Clinical Investigation|July 29, 2010
Seeing red: flushing out instigators of niacin-associated skin toxicityRichard L Dunbar, Joel M GelfandCurrent Treatment Options in Cardiovascular Medicine|May 26, 2005
Current Drug Options for Raising HDL CholesterolRichard L Dunbar, Daniel J RaderScience Translational Medicine|July 24, 2010
Could exercise metabolomics pave the way for gymnomimetics?Megan F Burke, Richard L Dunbar, Daniel J RaderAtherosclerosis|January 26, 2013
Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equationsEmil M deGoma, Richard L Dunbar, Douglas Jacoby, et al.The American Journal of Cardiology|November 30, 2014
Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemiaAmit V Khera, Arman Qamar, Muredach P Reilly, et al.Cardiovascular Research|August 25, 2025
Eicosapentaenoic acid (EPA) limits the more rapid oxidation of lipoprotein(a) [Lp(a)] compared with other ApoB particlesSamuel C R Sherratt, Peter Libby, Richard L Dunbar, et al.Pageof 4